Evaluation of CCND1 amplification and cyclinD1 expression: Diffuse and strong staining of cyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers

American Journal of Translational Research

Volumn 8, Issue 1, 2016, Pages 142-153

  Li, Zhishuang ^a   Cui, Jingjing ^a   Yu, Qiong ^b   Wu, Xiaojuan ^a   Pan, Aifeng ^a   Li, Li ^a  

^a SHANDONG UNIVERSITY   (China)

^b Central Hospital of Zaozhuang Mining Group   (China)

Author keywords

Breast cancer; CCND1; Cyclin D1; Predictive markers; Target therapy

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CCND1 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TUMOR VOLUME;

EID: 84957795105     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL and Robertson JF. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999; 5: 2069-2076.
4. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ. CDK-independent activation of estrogen receptor by cyclinD1. Cell 1997; 88: 405-415.
5. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R and Sauter G. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004; 64: 8534-8540.
6. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL and Dowsett M. CyclinD1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006; 19: 999-1009.
7. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, Reis-Filho JS and Ellis IO. CCND1 amplification and cyclinD1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008; 109: 325-335.
8. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum D, Gaudray P and Theillet C. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer 1994; 9: 42-48.
9. Ormandy CJ, Musgrove EA, Hui R, Daly RJ and Sutherland RL. CyclinD1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003; 78: 323-335.
10. Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R and Sutherland RL. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 1997; 15: 1617-1623.
11. Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JF, Nicholson RI and Sutherland RL. EMS1 gene expression in primary breast cancer: relationship to cyclinD1 and oestrogen receptor expression and patient survival. Oncogene 1998; 17: 1053-1059.
12. Holm K, Staaf J, Jonsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringner M and Borg A. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Breast Cancer Res Treat 2012; 133: 583-594.
13. Tobin NP and Bergh J. Analysis of Cyclin D1 in Breast Cancer: A Call to Arms. Curr Breast Cancer Rep 2012; 4: 171-173.
14. Aaltonen K, Amini RM, Landberg G, Eerola H, Aittomaki K, Heikkila P, Nevanlinna H and Blomqvist C. CyclinD1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 2009; 113: 75-82.
15. Roy PG, Pratt N, Purdie CA, Baker L, Ashfield A, Quinlan P and Thompson AM. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer 2010; 127: 355-360.
16. Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Borresen-Dale AL, Levine AJ, Bhanot G and Ganesan S. Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. PLoS One 2012; 7: e38575.
17. Tabarestani S, Ghaderian SM, Rezvani H, Mirfakhraie R, Ebrahimi A, Attarian H, Rafat J, Ghadyani M, Alavi HA, Kamalian N, Rakhsha A and Azargashb E. Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. Cell Oncol (Dordr) 2014; 37: 107-118.
18. Keilty D, Buchanan M, Ntapolias K, Aleynikova O, Tu D, Li X, Shepherd L, Bramwell V and Basik M. RSF1 and not cyclinD1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial. PLoS One 2013; 8: e81740.
19. Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G and Trans Ai. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res 2012; 14: R57.
20. Sun Y, Luo D and Liao DJ. CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinog 2012; 11: 12.
21. Linke SP, Bremer TM, Herold CD, Sauter G and Diamond C. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 2006; 12: 1175-1183.
22. Burandt E, Grunert M, Lebeau A, Choschzick M, Quaas A, Janicke F, Muller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkotter U, Simon R, Sauter G and Wilczak W. Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer 2014;
23. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ and Panel M. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
24. Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H and Landberg G. The cyclinD1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002; 21: 4680-4690.
25. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O and Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005; 65: 8009-8016.
26. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP and Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966-1975.
27. Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirstrom K, Harkonen P, Lamb R and Landberg G. Down-regulation of the oncogene cyclinD1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol 2010; 177: 2886-2897.
28. Peters G, Fantl V, Smith R, Brookes S and Dickson C. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat 1995; 33: 125-135.
29. Bieche I, Olivi M, Nogues C, Vidaud M and Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as deter mined by real-time quantitative PCR assays. Br J Cancer 2002; 86: 580-586.
30. Pegram MD, Pauletti G and Slamon DJ. HER-2/ neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52: 65-77.
31. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC and Ashworth A. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol 2006; 19: 307-319.
32. Camp RL, Charette LA and Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949.
33. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP and Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159: 2249-2256.
34. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
35. Wolff AC1, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
36. Matsuyama H, Pan Y, Mahdy EA, Malmstrom PU, Hedrum A, Uhlen M, Busch C, Hirano T, Auer G, Tribukait B, et al. p53 deletion as a genetic marker in urothelial tumor by fluorescence in situ hybridization. Cancer Res 1994; 54: 6057-6060.
37. Harvey JM, Clark GM, Osborne CK and Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
38. Jia L, Yuan Z, Wang Y, Cragun JM, Kong B and Zheng W. Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. Mod Pathol 2015; 28: 118-127.